The Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of a host of th 9 July 2021
The US Food and Drug Administration (FDA) has approved an expanded label for Keytruda (pembrolizumab), Merck & Co’s anti-PD-1 therapy, as monotherapy for the tr 6 July 2021
The European Commission (EC) has approved Sanofi (Euronext: SAN) and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) to treat locally advanced or metastatic bas 25 June 2021
Sanofi has presented detailed results from the Phase III VOYAGE trial, showing that Dupixent (dupilumab) significantly reduced severe asthma attacks, and within 17 May 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.